期刊文献+

Graves病^131I治疗前和治疗一年中促甲状腺素受体抗体水平的动态变化 被引量:5

Dynamics of thyroid-stimulating hormone receptor antibody during one year after ^131I treatment of Graves' disease
原文传递
导出
摘要 对157例Graves病^131I门诊治疗的病例进行回顾性研究。按^131I治疗1年后甲状腺功能状态分成3组:缓解组(FT3、FT4正常)、部分缓解组(FT3、FT4未降至正常范围)、甲减组(FT3、FT4低于正常)。治疗前促甲状腺素受体抗体(TRAb)的阳性率为88.5%。^131I治疗后,TRAb在3。6个月时达高峰,之后逐渐下降。甲状腺重量、显著升高的TRAb(t〉405U/L)、FT3、FT4水平是评估预后的指标。 One hundred and fifty-seven patients with Graves' disease treated with ^131I from July 2001 to March 2003 were studied retrospectively. According to the thyroid function one year after ^131I therapy, the patients were divided into 3 groups : remission group with normal FT3, FT4, partial remission group with above normal levels of FT3, FT4, and hypothyroid group with lowered levels of FT3 , FT4. Prior to ^131I treatment the thyroid-stimulating hormone receptor antibody (TRAb) was positive in 88.5% of the patients. After the therapy, TRAb levels rose transiently and reached the peak within 3-6 months and then dropped gradually thereafter. The weight of pretreatment thyroid, high levels of TRAb (≥ 405 U/L ) and FT3, FT4 were predictors for the outcome of treatment.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2008年第5期529-530,共2页 Chinese Journal of Endocrinology and Metabolism
关键词 格雷夫斯病 碘放射性同位素 促甲状腺素受体抗体 Graves' disease Iodine radioisotopes Thyrotropin receptor antibodies
  • 相关文献

参考文献10

  • 1Takamura Y, Nakano K, Uruno T, et al. Changes in serum TSH receptor antibody (TRAB) values in patients with Graves' disease after total or subtotal thyroidectomy. Endocrine J, 2003,50:595-601.
  • 2Wiersinga WM, Prummel MF. Pathogenesis of Graves' ophthalmopathycurrent understanding. J Clin Endocrinol metab, 2000,86:501-503.
  • 3廖二元.甲状腺功能亢进症[A].叶任高主编.内科学:第5版[C].北京:人民卫生出版社,2001.738.
  • 4Saravanan P, Dayan CM. Thyroid autoantibodies. Endocrinol Metab Clin Noah Am, 2001,30:315-337.
  • 5Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol metab, 1998,83:40-46.
  • 6Bonnema SJ, Bartalena L, Toft AD, et al. Controversies in radioiodine therapy : relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol, 2002, 14-7:1-11.
  • 7Orgiazzi J. Anti-TSH receptor antibodies in clinical practice. Endocrinol Metab Clin North Am, 2000,29:339-355.
  • 8Gupta MK. Thyrotropin-receptor antibodies in thyroid disease : advances in detection techniques and clinical applications. Clinica Chimica Acta, 2000,293 : 1-29.
  • 9Syed AA, Evans C, Ludgate M, et al. Early changes in thyroidstimulating antibody activity following radioiodine therapy. Med Princ Pract, 2003,12:266-268.
  • 10Wallaschofski H, Miehle K, Mayer A, et al. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment. Horm Metab Mes, 2002,34 : 383-388.

共引文献5

同被引文献44

  • 1庞华,谭本旭,罗加.^(131)I治疗Graves病疗效影响因素分析[J].中华核医学杂志,2003,23(6):337-338. 被引量:10
  • 2滕卫平.甲状腺功能亢进症[M]//陆再英,钟南山.内科学.第7版.北京:人民卫生出版社,2008:712-721.
  • 3陈跃,匡安仁.内分泌疾病的治疗[M]//李少林.核医学.7版.北京:人民卫生出版社,2008:259-260.
  • 4Kilpatrick R, Blomfield GW, Neal FE, et al. Carcinoma of the thyroid :Review of 100 cases[ J]. Q J Med, 1957,26 ( 2 ) :209-233.
  • 5管昌田.放射性碘治疗甲状腺功能亢进症的现状及展望.国外医学:放射医学核医学分册,1987,11(3):167-173.
  • 6卢倜章.放射性核素治疗甲状腺功能亢进症[M]//卢周章,秦明秀.放射性核素治疗学.天津:天津科学技术出版社,1994:145-173.
  • 7Maxon HR,Thomas SR,Chen IW,et al. The role of nuclear medicine in the treatment of hyperthyroidism and well differentiated thyroid adenocarcinoma [ J ]. Clin Nucl Med, 1981,6 ( 10 ) :87-98.
  • 8Robertson JS, Gorman CA. Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism [ J]. J Nucl Med, 1976,17 (9) : 826-835.
  • 9Thompson DE, Mahuchi K, Ron E,et al. Cancer incidence in atomic bomb surviors. Part Ⅱ :Solid tumors. 1958-1987 [ J]. Radiol Res, 1994,137 (2) : S17-S67.
  • 10Nielsen V, Bonnema S, Boel-Jorgensen H,et al. Stimulation with 0. 3mg recombinant human thyrotropin prior to Iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter:a prospective randomized double-blind trial [ J ]. Arch Intern Med, 2006,166 (14) : 1476-1482.

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部